NK Cell therapies - Pipeline Insight, 2022
![](/report_cover/8047/nk-cell-therapies-pipeline-insight-2022_en.gif)
This report can be delivered to the clients within 90 hours
DelveInsight’s, “NK Cell therapy - Pipeline Insight, 2022” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in NK Cell therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
NK Cell therapy: Overview
Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cells have cytotoxic small granules, which contain special proteins such as perforins and proteases, are known as granzymes in their cytoplasm. NK cells surveillance system includes a number of cell surface activating and inhibitory receptors that control the cytolytic activity of NK cells by sending an either stimulatory or inhibitory signal. The fine balance between activation and inhibition NK cells decides their final action. The inhibitory receptor’s ligands include self-MHC class I molecules that are present on all nucleated cells of the body which helps in avoiding the NK cells activity on normal cells. NK cells have also potent producers of inflammatory cytokines, such as TNF-? and IFN-?. The activation of NK cells is controlled by a dynamic balance between the positive and negative signals. The encounter between the NK cell and target cell results in adhesion and conjugation (Immune Synapse). The NK cells activating receptors induces the phosphorylation of ITAM or kinase and tight actin cytoskeleton rearrangements that, in turn, lead to a more stable conjugation (Activation). Activation of NK cells also takes place by the locally secreted cytokines by other immune cells, inducing various types of immune-related gene expression including cytokines, NK cell effectors, and non-coding microRNAs (miRNAs). NK cell-based cancer immunotherapy aims at reversing the tumor-induced NK cell dysfunction that is observed in patients with cancer and to increase and sustain NK cell effector functions. Therapies involving NK cells may either activate endogenous NK cells or involve the transfer of exogenous cells by hematopoietic stem cell transplantation (HSCT) or adoptive cell therapy.
'NK Cell therapy - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the NK Cell therapy pipeline landscape is provided which includes the disease overview and NK Cell therapy treatment guidelines. The assessment part of the report embraces, in depth NK Cell therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, NK Cell therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the NK Cell therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
NK Cell therapy Emerging Drugs
Further product details are provided in the report……..
NK Cell therapy: Therapeutic Assessment
This segment of the report provides insights about the different NK Cell therapy drugs segregated based on following parameters that define the scope of the report, such as:
NK Cell therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses NK Cell therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NK Cell therapy drugs.
NK Cell therapy Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “NK Cell therapy - Pipeline Insight, 2022” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in NK Cell therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
NK Cell therapy: Overview
Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cells have cytotoxic small granules, which contain special proteins such as perforins and proteases, are known as granzymes in their cytoplasm. NK cells surveillance system includes a number of cell surface activating and inhibitory receptors that control the cytolytic activity of NK cells by sending an either stimulatory or inhibitory signal. The fine balance between activation and inhibition NK cells decides their final action. The inhibitory receptor’s ligands include self-MHC class I molecules that are present on all nucleated cells of the body which helps in avoiding the NK cells activity on normal cells. NK cells have also potent producers of inflammatory cytokines, such as TNF-? and IFN-?. The activation of NK cells is controlled by a dynamic balance between the positive and negative signals. The encounter between the NK cell and target cell results in adhesion and conjugation (Immune Synapse). The NK cells activating receptors induces the phosphorylation of ITAM or kinase and tight actin cytoskeleton rearrangements that, in turn, lead to a more stable conjugation (Activation). Activation of NK cells also takes place by the locally secreted cytokines by other immune cells, inducing various types of immune-related gene expression including cytokines, NK cell effectors, and non-coding microRNAs (miRNAs). NK cell-based cancer immunotherapy aims at reversing the tumor-induced NK cell dysfunction that is observed in patients with cancer and to increase and sustain NK cell effector functions. Therapies involving NK cells may either activate endogenous NK cells or involve the transfer of exogenous cells by hematopoietic stem cell transplantation (HSCT) or adoptive cell therapy.
'NK Cell therapy - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the NK Cell therapy pipeline landscape is provided which includes the disease overview and NK Cell therapy treatment guidelines. The assessment part of the report embraces, in depth NK Cell therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, NK Cell therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence NK Cell therapy R&D. The therapies under development are focused on novel approaches to treat/improve NK Cell therapy.
This segment of the NK Cell therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
NK Cell therapy Emerging Drugs
- Monalizumab: Innate Pharma
- NKTR-214 (Bempegaldesleukin): Nektar Therapeutics
- ALECSAT: CytoVac
- CellProtect: XNK Therapeutics
- NK-92: ImmunityBio
- haNk: ImmunityBio
- K-NK002: Kiadis Pharma
Further product details are provided in the report……..
NK Cell therapy: Therapeutic Assessment
This segment of the report provides insights about the different NK Cell therapy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in NK Cell therapy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
NK Cell therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses NK Cell therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NK Cell therapy drugs.
NK Cell therapy Report Insights
- NK Cell therapy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing NK Cell therapy drugs?
- How many NK Cell therapy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of NK Cell therapy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the NK Cell therapy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for NK Cell therapy and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
NK Cell therapy: Overview
Causes
Mechanism of Action
NK Cell activation
NK cells in cancer
NK based immunotherapy
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
NK Cell therapy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
NK Cell therapy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
NK Cell therapy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Monalizumab: Innate Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ALECSAT: CytoVac
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Comparative Analysis
Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
NK Cell therapy Key Companies
NK Cell therapy Key Products
NK Cell therapy- Unmet Needs
NK Cell therapy- Market Drivers and Barriers
NK Cell therapy- Future Perspectives and Conclusion
NK Cell therapy Analyst Views
NK Cell therapy Key Companies
Appendix
Executive Summary
NK Cell therapy: Overview
Causes
Mechanism of Action
NK Cell activation
NK cells in cancer
NK based immunotherapy
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
NK Cell therapy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
NK Cell therapy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
NK Cell therapy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Monalizumab: Innate Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ALECSAT: CytoVac
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Comparative Analysis
Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
NK Cell therapy Key Companies
NK Cell therapy Key Products
NK Cell therapy- Unmet Needs
NK Cell therapy- Market Drivers and Barriers
NK Cell therapy- Future Perspectives and Conclusion
NK Cell therapy Analyst Views
NK Cell therapy Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for NK Cell therapy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for NK Cell therapy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for NK Cell therapy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for NK Cell therapy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products